Ascopar (acetylsalicylic acid) tablets №10

active ingredients: acetylsalicylic acid, paracetamol, caffeine;

1 tablet contains acetylsalicylic acid 200 mg, paracetamol 200 mg, caffeine 40 mg;

excipients: potato starch, calcium stearate, povidone.

Pills.

Basic physical and chemical properties: white or almost white tablets, flat-cylindrical with a chamfer and a notch. Marbling is allowed on the surface of the tablets.

Analgesics and antipyretics. Paracetamol, combinations without psycholeptics. ATX code N02B E51.

Ascopar (acetylsalicylic acid) has analgesic, antipyretic, anti-inflammatory, antiplatelet effect; the components included in its composition enhance the effects of each other.

The analgesic effect of acetylsalicylic acid is associated with inhibition of the synthesis of prostaglandins in inflamed tissues (peripheral effect) and with an effect on the centers of the hypothalamus (central effect).

Violation of the synthesis of thromboxane A2 in platelets causes an antiplatelet effect.

The antipyretic effect is due to the inhibition of the synthesis of PGF2 prostaglandins in the hypothalamus in response to exposure to endogenous pyrogens.

Paracetamol has an analgesic, antipyretic and weak anti-inflammatory effect, which is associated with its effect on the thermoregulatory center in the hypothalamus and a less pronounced ability to inhibit the synthesis of prostaglandins in peripheral tissues.

Caffeine in a small dose in this combination practically does not have a stimulating effect on the central nervous system, however, it helps to normalize the tone of the brain vessels and accelerate blood flow, enhances the effect of analgesics and antipyretics.

After oral administration, the components of Ascopar (acetylsalicylic acid) are rapidly absorbed from the digestive tract.

Pain syndrome of mild or moderate severity (headache, migraine, toothache, neuralgia, muscle and joint pain, pain during menstrual irregularities); as an antipyretic in diseases accompanied by fever.

Hypersensitivity to the components of Ascopar (acetylsalicylic acid), hypersensitivity to other xanthine derivatives (theophylline, theobromine), other salicylates. Congenital hyperbilirubinemia, severe renal or hepatic failure, Gilbert’s syndrome, congenital deficiency of glucose-6-phosphate dehydrogenase. Blood diseases, hemophilia, increased tendency to bleeding, hypothrombinemia, hemorrhagic diathesis, anemia, leukopenia, thrombosis, thrombophlebitis, hemorrhagic diseases. Acute gastrointestinal ulcers, gastrointestinal bleeding, surgical interventions accompanied by significant bleeding. States of increased arousal, sleep disturbances, old age, alcoholism, glaucoma, hyperthyroidism, acute pancreatitis, prostatic hypertrophy, severe forms of diabetes mellitus, severe arterial hypertension. Severe diseases of the cardiovascular system, including rhythm disturbances, paroxysmal tachycardia, severe heart failure, severe coronary heart disease, acute myocardial infarction, a tendency to vasospasm, severe atherosclerosis. Bronchial asthma, urticaria or rhinitis caused by taking salicylates or other NSAIDs in history.

Do not use together with MAO inhibitors (MAO) and within 2 weeks after discontinuation of MAO inhibitors, contraindicated in patients taking tricyclic antidepressants, β-blockers, combination with methotrexate at a dose of 15 mg / week or more is contraindicated.